<DOC>
	<DOCNO>NCT00758485</DOCNO>
	<brief_summary>The current trial design demonstrate faster recovery participant undergo elective surgery require profound neuromuscular blockade induce rocuronium fourth twitch/first twitch ( T4/T1 ) ratio 0.9 , reversal target depth neuromuscular blockade ( NMB ) 1-2 Post Tetanic Count ( PTC ) 4.0 mg.kg-1 Sugammadex compare Placebo , evaluate safety 4.0 mg.kg-1 Sugammadex evaluate Operating Room ( OR ) Post Anesthetic Care Unit ( PACU ) length stay participant .</brief_summary>
	<brief_title>Comparing 4.0 mg.Kg-1 Sugammadex With Placebo Reversal Profound Neuromuscular Blockade ( P05767 )</brief_title>
	<detailed_description />
	<mesh_term>Rocuronium</mesh_term>
	<criteria>Male female participant American Society Anesthesiologists ( ASA ) class 1 , 2 3 Age &gt; =18 year Scheduled undergo surgery require profound NMB cardiovascular , gynaecologic , neurologic thoracic surgical procedure general anesthesia require neuromuscular relaxation rocuronium endotracheal intubation applicable maintenance NMB position allow neuromuscular monitoring Given write informed consent Participants know suspected neuromuscular disorder affect NMB</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>